| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Arthur Greenberg last filed a Form 4 in December 2016, as Director at GALT. Arthur Greenberg's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 109,445 shares of GALT. Net of sales, the GALT filings show accumulation of 1,666 shares.
Arthur Greenberg has 3 Form 4 filings on record from March 2015 to December 2016, all as Director at Galectin Therapeutics (GALT), 2015–2016.
The 3 reported transactions were 1 option or other derivative award, 1 open-market purchase and 1 stock award.
Counted by filing, the open-market trades come to 1 purchase worth about $3K and no sales.
The only open-market purchase was 1,666 shares of GALT at an average $1.72 on January 5, 2016, about $3K.
Shares as reported in the last Form 4 for each company; the most recent is from December 2016. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2016 | GALT Galectin Therapeutics Inc | Director | Buy | 1,666 | $1.72 | $2,865.52 | +1.5% |